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Abstract
Background
The World Health Organization recommends annual mass azithromycin administration in
communities with at least 10% prevalence of trachomatous inflammation–follicular (TF) in
children, with further treatment depending on reassessment after 3–5 years. However, the
effect of stopping mass azithromycin distribution after multiple rounds of treatment is not
well understood. Here, we report the results of a cluster-randomized trial where communi-
ties that had received 4 years of treatments were then randomized to continuation or discon-
tinuation of treatment.
Methods and findings
In all, 48 communities with 3,938 children aged 0–9 years at baseline in northern Ethiopia
had received 4 years of annual or twice yearly mass azithromycin distribution as part of the
TANA I trial. We randomized these communities to either continuation or discontinuation of
treatment. Individuals in the communities in the continuation arm were offered either annual
or twice yearly distribution of a single directly observed dose of oral azithromycin. The pri-
mary outcome was community prevalence of ocular chlamydial infection in a random sam-
ple of children aged 0–9 years, 36 months after baseline. We also assessed the change
from baseline to 36 months in ocular chlamydia prevalence within each arm. We compared
36-month ocular chlamydia prevalence in communities randomized to continuation versus
discontinuation in a model adjusting for baseline ocular chlamydia prevalence. A secondary
prespecified analysis assessed the rate of change over time in ocular chlamydia prevalence
between arms. In the continuation arm, mean antibiotic coverage was greater than 90% at
all time points. In the discontinuation arm, the mean prevalence of infection in children aged
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0–9 years increased from 8.3% (95% CI 4.2% to 12.4%) at 0 months to 14.7% (95% CI
8.7% to 20.8%, P = 0.04) at 36 months. Ocular chlamydia prevalence in communities where
mass azithromycin distribution was continued was 7.2% (95% CI 3.3% to 11.0%) at baseline
and 6.6% (95% CI 1.1% to 12.0%, P = 0.64) at 36 months. The 36-month prevalence of ocu-
lar chlamydia was significantly lower in communities continuing treatment compared with
those discontinuing treatment (P = 0.03). Limitations of the study include uncertain gener-
alizability outside of trachoma hyperendemic regions.
Conclusions
In this study, ocular chlamydia infection rebounded after 4 years of periodic mass azithromy-
cin distribution. Continued distributions did not completely eliminate infection in all communi-
ties or meet WHO control goals, although they did prevent resurgence.
Trial registration
This study was prospectively registered at clinicaltrials.gov (clinicaltrials.gov
NCT01202331).
Author summary
Why was this study done?
• Trachoma is the leading infectious cause of blindness in the world.
• Although trachoma is disappearing globally, severe trachoma persists in a few districts
in Ethiopia.
• Periodic mass azithromycin distribution reduces infection to very low levels, but com-
plete elimination in all communities has proven difficult.
What did the researchers do and find?
• We assessed whether mass azithromycin distributions could be discontinued after 4
years of treatment in communities with severe trachoma in northern Ethiopia.
• A subset of communities that had participated in a previous cluster-randomized trial
were re-randomized to continuation or discontinuation of mass azithromycin
distribution.
• Ocular chlamydia infection, which causes trachoma, was found to increase over time
after mass azithromycin distribution was stopped. Compared to communities where
mass azithromycin distribution was continued, communities where distribution was
stopped had significantly higher rates of ocular chlamydia infection after 3 years of
study.
• Despite 7 years of treatment in communities continuing mass azithromycin distribu-
tion, infection was not eliminated in all communities.
Mass azithromycin for hyperendemic trachoma
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What do these findings mean?
• Trachoma may be the first bacterial disease of humans to be eliminated by a public
health program; however, these results indicate that stopping mass azithromycin treat-
ment in some severely affected areas is not realistic.
• Alternative strategies for trachoma elimination may be required for the most severely
affected areas.
Introduction
Mass distribution of azithromycin is a key component of the World Health Organization’s
SAFE (surgery for trichiasis, antibiotics, facial cleanliness, and environmental improvement)
strategy for trachoma control [1–3]. Antibiotics (azithromycin), facial cleanliness, and envi-
ronmental improvements (e.g., latrinization and water improvements) are interventions
aimed at reducing community transmission of the strains of ocular chlamydia that cause tra-
choma [4,5]. Although facial cleanliness and environmental improvements are associated with
decreased clinical trachoma, we have no evidence that facial hygiene or environmental
improvements have any effect on ocular chlamydia [6–8]. On the other hand, a single mass azi-
thromycin distribution has been shown to dramatically reduce the prevalence of ocular chla-
mydia [9,10]. The WHO currently recommends 3 to 5 rounds of annual mass azithromycin
distributions for communities in which the district prevalence of trachomatous inflamma-
tion–follicular (TF) among 1- to 9-year-old children exceeds 10%, followed by an impact sur-
vey to assess whether treatment should be continued. If the district prevalence of TF is below
10% during the impact survey, then community-level surveys should be done, and any com-
munities with a prevalence of TF < 5% should have mass antibiotic treatments discontinued
[11].
The WHO recommendation for when to continue mass azithromycin distribution, while
extremely valuable to trachoma programs, is based on very limited empirical evidence. Some
studies have found evidence to support the existence of an Allee-like effect, in which chlamyd-
ial infections fade away if reduced below some low threshold [9,12–15]. In contrast, other stud-
ies have found that infection rapidly rebounds once repeated mass azithromycin distributions
are stopped [16,17].
In a previous trial (TANA I), we compared repeated annual versus biannual mass azithro-
mycin distributions to determine whether more frequent azithromycin treatment would lead
to better control of ocular chlamydia [18]. The trial found a marked reduction in the preva-
lence of ocular chlamydia among 0- to 9-year-olds in both the annual and biannual groups
over the duration of the 3.5-year study, but no significant difference between the 2 treatment
strategies at the final study visit [18]. Following the completion of this study, we initiated a
continuation trial (TANA II) in which communities from the annual and biannual arms of the
original trial were re-randomized to continuing or stopping mass azithromycin distribution to
evaluate the need for continued mass azithromycin distributions in areas that have received
multiple rounds of mass azithromycin distribution. Here, we report the effect of continuation
versus discontinuation of mass azithromycin treatment following 4 years of repeated annual
or biannual mass azithromycin distribution on ocular chlamydial infection in a hyperendemic
region of Ethiopia.
Mass azithromycin for hyperendemic trachoma
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Methods
TANA (Trachoma Amelioration in Northern Amhara, ClinicalTrials.gov NCT00322972) was
a community-randomized trial that compared different mass azithromycin strategies for
reducing ocular chlamydial infection in a hyperendemic area of Ethiopia. The present report
describes 4 arms from its continuation trial, Tripartite International Research for the Elimina-
tion of Trachoma (TIRET) (ClinicalTrials.gov NCT01202331), also known as and referred to
here as TANA II. The trial received ethical approval from the University of California, San
Francisco; Emory University; and the Ethiopian Ministry of Science and Technology. Because
illiteracy was common among study participants, we obtained verbal informed consent for all
study procedures. Caregivers provided verbal consent for children to participate, and commu-
nity leaders provided consent for their community to participate in the study.
TANA I overview
TANA I was a cluster-randomized trial conducted in the Goncha Siso Enese woreda (district) of
the Amhara Region of Ethiopia from June 1, 2006, to December 2, 2009 [18]. All communities in
the district were eligible for randomization excluding the town of Gindewoin, as it is a semi-urban
area with a lower prevalence of trachoma. In the trial, we randomized 72 government-defined sub-
divisions known as subkebeles to 1 of 6 different treatment strategies, including 12 subkebeles to
annual mass azithromycin treatments and 12 subkebeles to biannual mass azithromycin treat-
ments (Fig 1). Subkebeles consisted of 4–6 government-defined units known as state teams (com-
munities). We treated all communities of the subkebele identically, and performed monitoring for
ocular chlamydia in a single sentinel state team from the subkebele. We collected conjunctival
swabs every 6 months from a random sample of community members, and processed swabs for
chlamydia testing using AMPLICOR CT (Roche Molecular Diagnostics, Pleasanton, CA).
TANA II overview
We conducted the TANA II continuation trial from November 1, 2010, until November 8, 2013.
The TANA II trial population consisted of 48 state teams that had received annual mass azithro-
mycin distributions and 24 state teams that had received biannual mass azithromycin distributions
during TANA I. State teams were randomly selected stratified by subkebele, with 4 state teams
from each of the 12 annually treated subkebeles and 2 state teams from each of the 12 biannually
treated subkebeles. We randomized the 4 state teams in each annually treated subkebele to 1 of the
following treatment strategies: (1) discontinuation of mass treatments, (2) continued annual mass
azithromycin treatments, (3) azithromycin treatments targeted to preschool children, or (4) azi-
thromycin treatments targeted to households containing children with clinically active trachoma.
We randomized the 2 state teams from each biannually treated subkebele to either discontinuation
of mass treatments or to continued biannual mass azithromycin distributions. As depicted in Fig
1, the present report includes 48 state teams randomized into 4 treatment groups: continuation of
annual mass azithromycin (N= 12), cessation of annual mass azithromycin (N= 12), continuation
of biannual mass azithromycin (N= 12), and cessation of biannual mass azithromycin (N= 12).
The 2-stage randomization means that these 4 groups were randomly drawn from the same
underlying population and can thus be validly compared with each other. The trial protocol and
outcomes were prespecified, and there were no changes to the methods after commencement.
Randomization and masking
TCP performed the randomization in the statistical package R (R Foundation for Statistical
Computing, Vienna, Austria). State teams from the annual and biannual arms of TANA I were
Mass azithromycin for hyperendemic trachoma
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Fig 1. CONSORT diagram. Age range for children is 0–9 years; age range for adults is 10 years and older.
https://doi.org/10.1371/journal.pmed.1002633.g001
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randomized to discontinue or continue their treatment strategy. All state teams were enrolled
prior to randomization. Study participants were not masked to their state team’s treatment
allocation. Field staff were not informed of, and laboratory personnel were masked to, the state
team’s treatment allocation.
Intervention
In both TANA I and TANA II, we performed an annual door-to-door enumerative census. In
state teams assigned to treatment, azithromycin was offered to all community members aged 6
months and up (approximately 20 mg/kg using height-based dosing for children, up to a maxi-
mum of 1 g) [19]. Children less than 6 months, pregnant women, and those allergic to macro-
lide antibiotics were offered 2 tubes of topical tetracycline instead, to be used twice daily for 6
weeks. Antibiotic coverage was defined as the proportion of individuals from the most recent
census who received either oral azithromycin or topical tetracycline. An adverse event notifica-
tion system was put in place for individuals to notify the village informant and the Ethiopian
study coordinator.
Monitoring
The primary outcome was prevalence of ocular chlamydia infection as detected by PCR. Active
trachoma was a prespecified secondary outcome and is included in this report as it is an impor-
tant component of monitoring trachoma control programs [20]. We performed annual assess-
ments in the same populations as in TANA I: a random sample of 50 children aged 0–9 years
and a random sample of 50 individuals aged 10 years and older (“adults”) from each state team
based on the most recent census. To assess active trachoma, at each monitoring visit, we exam-
ined the everted upper right tarsal conjunctiva for signs of trachoma according to the WHO
simplified trachoma grading system, specifically assessing the presence of TF and trachomatous
inflammation–intense. To assess ocular chlamydia, we then collected a conjunctival specimen
by passing a Dacron swab 3 times against the everted tarsal conjunctiva, rotating the swab 120˚
between each pass. We stored swabs on ice for<8 hours while in the field, then at −20˚C until
transport to the lab, at 4˚C for<24 hours during transport, and finally at −80˚C until process-
ing. We performed chlamydial testing with the Abbott m2000 platform on pools of 5 randomly
selected swabs, with pools stratified by community and age group. We estimated the prevalence
of infection most likely to have resulted in the pooled result, as previously described [21].
Sample size determination
The sample size was based on the primary outcome for the discontinuation and continuation
arms, with assumptions based on the results of previous studies (the Trachoma Elimination Fol-
low-up study and TANA I) [18,22]. The standard deviation after 1 year of treatment in TANA I
was 0.043, and we conservatively assumed a standard deviation of 0.05 for sample size planning.
For assessment of rebound of ocular chlamydia following discontinuation of treatment, a sam-
ple size of 12 state teams per arm was determined to provide approximately 80% power to detect
a difference of 5% assuming a paired t test. For comparison of continued annual versus contin-
ued biannual treatment, a sample size of 12 state teams per arm was determined to provide
approximately 80% power to detect a 6% difference in ocular chlamydia prevalence.
Statistical considerations
All analyses were conducted at the level of the unit of randomization, the state team, to account
for the clustered design of the trial. We estimated the prevalence of ocular chlamydia and
Mass azithromycin for hyperendemic trachoma
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active trachoma in each state team at the community level as described above. The prespecified
primary outcome was the prevalence of ocular chlamydia in children aged 0–9 years at 36
months after the baseline visit of TANA II. All analyses were conducted in Stata 14.2 (Stata-
Corp, College Station, TX).
Longitudinal changes in prevalence. When analyzing the change in prevalence longitudi-
nally, we analyzed prevalence itself (non-transformed). The prespecified primary analysis was
the difference in prevalence from TANA II baseline to 36 months in the discontinuation arm,
with communities that had had annual and biannual azithromycin distribution in TANA I
aggregated together. In communities randomized to stopping mass azithromycin distribution,
we first tested whether the prevalence of ocular chlamydia at 36 months was different from
that at the baseline TANA II visit using a paired t test. As a prespecified secondary analysis, we
modeled chlamydia prevalence over all 4 study visits using a mixed effects linear regression
model in which the study community and its study visit were designated as random effects
(allowing for a random slope and random intercept for each community’s infection results
over time), with treatment arm as a fixed effect. As a secondary analysis, we repeated the analy-
sis with a Wilcoxon signed-rank test. A similar analytic strategy was used to assess the preva-
lence of ocular chlamydia over time in the continuation arm.
Comparison of continuation versus discontinuation. In analyses comparing the 2 arms,
we square-root-transformed the prevalence to improve the model fit. Because communities
were re-randomized, we included TANA II baseline prevalence as a covariate in models of
continuation versus discontinuation of treatment. The prespecified analysis compared the
prevalence of infection at 36 months (i.e., 90 months after randomization in TANA I) between
the discontinuation and continuation arms in a multiple linear regression with a term for
TANA II baseline ocular chlamydia prevalence. As a prespecified sensitivity analysis, we
included data from all 4 TANA II monitoring visits in a mixed effects linear regression in
which the study community and its study visit were designated as random effects, allowing for
a random slope and random intercept for each community’s infection results over time, with
treatment arm as a fixed effect. A Monte Carlo permutation test stratified by TANA I study
arm with 10,000 replications was used to calculate the P-value. As a sensitivity analysis, we
compared ocular chlamydia in communities in the continuation and discontinuation arms
separately by antibiotic distribution schedule (e.g., annual versus biannual), with an interac-
tion term between TANA I study arm and continuation versus discontinuation. A similar ana-
lytic approach was used for TF outcomes.
Comparison of annual versus biannual treatment. To compare the results of communi-
ties continuing annual versus continuing biannual mass azithromycin distribution, we used a
multiple linear regression model with terms for the TANA I baseline value and distribution
schedule. Because communities were not re-randomized to annual versus biannual treatment
at the start of TANA II, we included the TANA I baseline value: inclusion of the TANA II base-
line value would have been a post-randomization correction.
Results
During the first TANA trial, 12 subkebeles received 4 annual mass azithromycin distributions
and 12 subkebeles received 8 biannual mass azithromycin distributions over 3 years, with anti-
biotic coverage generally exceeding 80% in each community [18]. The results of the TANA I
trial have been reported previously [18]. Briefly, the prevalence of ocular chlamydial infection
in 0- to 9-year-olds as assessed by AMPLICOR decreased in both of the treatment groups after
3 years of repeated mass azithromycin distributions, from 41.9% to 1.9% in the annual group
and from 38.3% to 3.2% in the biannual group. The baseline visit for TANA II took place 54
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months after the baseline TANA I visit, which was 18 months after the final mass azithromycin
distribution in the annually treated group, and 12 months after the final mass azithromycin
distribution in the biannually treated group. Community characteristics for the baseline
TANA II visit are shown in Table 1. Antibiotic coverage during TANA II for the 24 communi-
ties randomized to continuation of annual or biannual mass azithromycin distribution gener-
ally exceeded 80% at each distribution (Table 2). No adverse events were reported in the study.
Tables 3 and 4 show the prevalence of ocular chlamydia among children aged 0–9 years in
each state team over time in the discontinuation and continuation arms, respectively. In the 24
state teams in which mass azithromycin distribution was discontinued, the mean prevalence of
ocular chlamydia infection increased from 8.3% (95% CI 4.2% to 12.4%) at TANA II baseline
to 14.7% (95% CI 8.7% to 20.8%) at the 36-month visit (P = 0.04, paired t test). This result was
consistent with a repeated measures model that included all time points (P = 0.01) and with a
Wilcoxon signed-rank test (P = 0.054). In contrast, the prevalence of ocular chlamydia did not
change markedly in the 24 state teams where mass azithromycin distribution was continued,
decreasing from 7.2% (95% CI 3.3% to 11.0%) at TANA II baseline to 6.6% (95% CI 1.1% to
12.0%) at 36 months (P = 0.85, paired t test), although a repeated measures model including all
time points indicated a decrease in prevalence over time (P = 0.047).
Table 1. Baseline characteristics by study arm.
Characteristic Discontinuation arm Continuation arm
Annual treatment Biannual treatment Annual treatment Biannual treatment
Number of state teams 12 12 12 12
Population1
0–9 years 360 (294–430) 274 (222–330) 300 (246–354) 330 (276–391)
10 years 90 (73–107) 75 (59–92) 81 (63–98) 93 (77–109)
Proportion female2
0–9 years 51.2% (48.2% to 53.9%) 49.5% (45.1% to 53.7%) 48.5% (45.7% to 51.7%) 49.3% (46.7% to 52.1%)
10 years 50.2% (48.6% to 51.8%) 53.2% (51.2% to 55.6%) 51.3% (49.5% to 53.0%) 50.8% (49.0% to 52.6%)
Proportion with TF/TI2
0–9 years 31.4% (22.3% to 39.8%) 34.5% (23.5% to 46.2%) 42.0% (34.7% to 49.0%) 35.9% (22.7% to 47.8%)
10 years 4.6% (1.9% to 9.2%) 4.2% (2.2% to 6.5%) 3.9% (2.2% to 6.1%) 2.9% (1.5% to 5.3%)
Elevation (m)2 2,585.5 (2,456.3 to 2,679.0) 2,606.4 (2,466.2 to 2,721.2) 2,510.3 (2,354.3 to 2,638.3) 2,531.2 (2,374.2 to 2,682.7)
TF, trachomatous inflammation–follicular; TI, trachomatous inflammation–intense.
1Range given in parentheses.
295% confidence interval given in parentheses.
https://doi.org/10.1371/journal.pmed.1002633.t001
Table 2. Antibiotic coverage by study arm.
Time point Discontinuation arm Continuation arm
Annual treatment Biannual treatment Annual treatment1 Biannual treatment1
0 months — — 93.7% (90.6% to 96.3%) 90.5% (87.9% to 93.4%)
6 months — — — 91.0% (88.3% to 93.4%)
12 months — — 92.9% (88.7% to 96.7%) 91.4% (88.5% to 94.3%)
18 months — — — 92.8% (90.7% to 95.0%)
24 months — — 95.8% (94.3% to 97.2%) 94.3% (91.7% to 96.7%)
30 months — — — 95.0% (93.5% to 96.5%)
36 months — — 91.9% (87.3% to 94.3%) 91.7% (87.8% to 94.7%)
195% confidence interval given in parentheses.
https://doi.org/10.1371/journal.pmed.1002633.t002
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At 36 months, there was no significant difference between state teams that had continued
to receive annual (9.9%, 95% CI 0% to 20.4%) versus biannual (3.3%, 95% CI 0% to 7.5%) mass
azithromycin distributions (P = 0.09, linear regression adjusted for TANA I baseline infection
prevalence).
The 24 state teams randomized to discontinuation of mass azithromycin distributions had
a significantly higher prevalence of ocular chlamydia at 36 months (14.7%, 95% CI 8.7% to
20.8%) compared to the 24 state teams that continued treatment (6.6%, 95% CI 1.1% to 12.0%;
P = 0.03, linear regression adjusted for prevalence of infection at TANA II baseline). In a pre-
specified sensitivity analysis including data from all time points in a repeated measures model
with a time by treatment arm interaction term, state teams randomized to discontinuation had
significantly higher ocular chlamydia prevalence over time compared to those that continued
mass azithromycin distributions (P-interaction = 0.02; Fig 2). There was no evidence of effect
modification by treatment frequency (annual or biannual) of the effect of continuation versus
discontinuation (P-interaction = 0.43). However, the reduction in prevalence in the continua-
tion compared to the discontinuation arm was greater in biannually treated communities
compared to annually treated communities (P = 0.04 biannual, P = 0.30 annual).
Table 3. Longitudinal prevalence of ocular chlamydia among a random sample of 0- to 9-year-old children after
discontinuation of mass azithromycin distribution.
State team Prevalence of ocular chlamydia, 0- to 9-year-old children
0 months 12 months 24 months 36 months
Annual treatment
1 2.0% (1/50) 8.9% (5/56) 3.8% (2/53) 13.9% (5/36)
2 5.7% (3/53) 6.0% (3/50) 15.1% (8/53) 16.0% (8/50)
3 12.7% (7/55) 6.1% (3/49) 18.5%)(10/54) 3.7% (2/54)
4 22.6% (12/53) 21.8% (12/55) 12.5% (6/48) 17.5% (7/40)
5 0.0% (0/46) 8.9% (4/45) 13.0% (7/54) 24.5% (12/49)
6 0.0% (0/51) 0.0% (0/43) 0.0% (0/44) 16.7% (8/48)
7 5.8% (3/52) 0.0% (0/37) 4.3% (2/46) 2.0% (1/50)
8 7.8%(4/51) 2.1% (1/47) 6.1% (3/49) 3.9% (2/51)
9 0.0% (0/26) 0.0% (0/28) 0.0% (0/26) 0.0% (0/21)
10 0.0% (0/52) 0.0% (0/56) 10.9% (6/55) 17.8% (8/45)
11 36.0% (18/50) 34.0% (16/47) 41.7% (20/48) 46.8% (22/47)
12 26.0% (13/50) 11.8% (6/51) 16.3% (8/49) 4.2% (2/48)
Mean (SD) 9.9% (12.1) 8.3% (10.4) 11.9% (11.3) 13.9% (13.0)
Biannual treatment
13 20.0% (8/40) 16.2% (6/37) 34.2% (13/38) 20.0% (8/40)
14 2.3% (1/44) 0.0% (0/43) 0.0% (0/36) 0.0% (0/37)
15 2.0% (1/50) 18.2% (10/55) 26.5% (13/49) 33.3% (17/51)
16 7.8% (4/51) 5.9% (3/51) 20.4% (10/49) 4.0% (2/50)
17 17.4% (8/46) 17.1% (7/41) 27.1% (13/48) 23.3% (10/43)
18 11.8% (6/51) 11.8% (6/51) 27.9% (12/43) 28.9% (11/38)
19 0.0% (0/49) 1.9% (1/52) 2.0% (1/50) 2.0% (1/50)
20 8.8% (3/34) 2.9% (1/35) 0.0% (0/32) 0.0% (0/27)
21 0.0% (0/48) 0.0% (0/52) 0.0% (0/55) 0.0% (0/49)
22 2.0% (1/49) 0.0% (0/44) 2.0% (1/51) 37.3% (19/51)
23 8.0% (4/50) 22.9% (11/48) 30.8% (16/52) 37.5% (18/48)
24 0.0% (0/40) 0.0% (0/34) 0.0% (0/45) 0.0% (0/41)
Mean (SD) 6.7% (6.9) 8.1% (8.6) 14.2% (14.5) 15.5% (16.0)
https://doi.org/10.1371/journal.pmed.1002633.t003
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Similar analyses were performed for TF in order to assess changes in clinically active tra-
choma (S1 and S2 Tables). In state teams in which mass azithromycin distribution was discon-
tinued, the mean prevalence of TF at TANA II baseline was 31.1% (95% CI 23.9% to 38.3%),
which increased to 39.9% (95% CI 32.5% to 47.4%) at 36 months (P = 0.02, paired t test). In
communities in which mass azithromycin distributions were continued, the mean TF preva-
lence at TANA II baseline was 37.9% (95% CI 30.0% to 45.8%), which decreased to 32.6%
(95% CI 24.8% to 40.4%) at 36 months (P = 0.05, paired t test). Communities in which mass
azithromycin distributions were discontinued had significantly higher TF prevalence at 36
months compared to communities in which mass azithromycin distributions were continued
(mean difference 11.7%, 95% CI 3.5% to 20.0%; P = 0.004, linear regression model adjusted for
TF prevalence at TANA II baseline). In a repeated measures sensitivity analysis, state teams
randomized to discontinuation of mass azithromycin distribution had significantly higher TF
prevalence over time (time by treatment P-interaction = 0.006, mixed effects model; Fig 3).
There was no significant difference in change in TF prevalence in communities originally
randomized to continuation versus discontinuation in annually and biannually treated com-
munities (P-interaction = 0.07), although, similar to ocular chlamydia prevalence, there was a
Table 4. Longitudinal prevalence of ocular chlamydia among a random sample of 0- to 9-year-old children with
continuation of mass azithromycin distribution.
State team Prevalence of ocular chlamydia, 0- to 9-year-old children
0 months 12 months 24 months 36 months
Annual treatment
25 0.0% (0/32) 5.6% (2/36) 5.9% (2/34) 5.3% (2/38)
26 10.0% (3/30) 0.0% (0/26) 0.0% (0/33) 0.0% (0/29)
27 11.1% (6/54) 2.1% (1/47) 4.8% (2/42) 2.4% (1/41)
28 11.1% (0/51) 16.7% (8/48) 0.0% (0/46) 5.7% (3/53)
29 0.0% (0/50) 0.0% (0/52) 0.0% (0/49) 20.4% (10/49)
30 16.7% (8/48) 0.0% (0/49) 1.9% (1/52) 3.6% (2/55)
31 8.0% (4/50) 0.0% (0/47) 0.0% (0/48) 1.9% (1/54)
32 3.7% (2/54) 2.0% (1/49) 0.0% (0/49) 2.5% (1/40)
33 0.0% (0/33) 0.0% (0/38) 2.4% (1/42) 0.0% (0/38)
34 1.9% (1/52) 0.0% (0/52) 0.0% (0/53) 5.8% (3/52)
35 11.8% (6/51) 6.0% (3/50) 7.7% (4/52) 59.5% (25/42)
36 30.8% (16/52) 11.5% (6/52) 3.9% (2/51) 11.3% (6/53)
Mean (SD) 8.8% (8.9) 3.7% (5.4) 2.2% (2.7) 9.9% (16.6)
Biannual treatment
37 23.4% (11/47) 5.0% (2/40) 7.5% (3/40) 0.0% (0/38)
38 0.0% (0/45) 4.8% (2/42) 0.0% (0/39) 0.0% (0/40)
39 3.6% (2/55) 1.9% (1/53) 0.0% (0/57) 0.0% (0/52)
40 0.0% (0/52) 0.0% (0/52) 0.0% (0/50) 0.0% (0/38)
41 27.7% (13/47) 2.1% (1/48) 20.0% (10/50) 1.9% (1/54)
42 4.3% (2/47) 12.7% (7/55) 3.8% (2/52) 23.4% (11/47)
43 0.0% (0/51) 0.0% (0/53) 0.0% (0/55) 0.0% (0/52)
44 0.0% (0/48) 0.0% (0/38) 0.0% (0/37) 6.3% (2/32)
45 0.0% (0/53) 0.0% (0/52) 0.0% (0/49) 0.0% (0/56)
46 4.0% (2/50) 0.0% (0/49) 0.0% (0/52) 5.8% (3/52)
47 4.0% (2/50) 4.0% (2/50) 8.5% (4/47) 1.9% (1/52)
48 0.0% (0/50) 0.0% (0/51) 0.0% (0/51) 0.0% (0/53)
Mean (SD) 5.6% (9.5) 2.5% (3.8) 3.3% (6.1%) 3.3% (6.7)
https://doi.org/10.1371/journal.pmed.1002633.t004
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stronger effect of continuation in biannually compared to annually treated communities (P =
0.001 biannual, P = 0.41 annual).
Discussion
Although continuation of mass azithromycin distribution led to reduced prevalence of ocular
chlamydia compared to communities in which distribution was discontinued, this study dem-
onstrates that even 7 rounds of mass azithromycin were not sufficient for elimination in an
area with hyperendemic trachoma. We initially hypothesized that several rounds of mass azi-
thromycin distributions might completely eliminate ocular chlamydia [18]. Previous work
with topical tetracycline ointment indicated that antibiotics alone would not be sufficient to
achieve trachoma elimination [23]. However, limitations of topical tetracycline, including long
treatment duration and poor adherence, may reduce its effectiveness [24]. Single-dose azithro-
mycin can overcome many of these limitations, although previous work has indicated ongoing
Fig 2. Longitudinal prevalence of ocular chlamydia in children aged 0–9 years. Black line is the mean in all communities. Grey lines are the prevalence in each
community.
https://doi.org/10.1371/journal.pmed.1002633.g002
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transmission of ocular chlamydia even after 3 years of implementation of the SAFE strategy in
a hyperendemic region of Ethiopia [25]. In the present study, in communities that had previ-
ously received 4 years of repeated mass azithromycin distributions, the prevalence of both clin-
ically active trachoma and ocular chlamydia infection stabilized if mass treatments were
continued, and increased if mass treatments were stopped. Continuing antibiotic distributions
was superior to discontinuing treatments, arguing for continued rounds of antibiotics if the
goal is maintaining low levels of ocular chlamydia.
Communities in which treatment was discontinued demonstrated a slower rate of return of
infection than previous studies in other hyperendemic regions of Ethiopia. A study in the
Gurage zone of Ethiopia found that the average prevalence of ocular chlamydia among 1- to
5-year-old children decreased from 64% to 2.6% after 4 biannual treatments, but returned to
25% 2 years later [26]. In contrast, the communities in the present study experienced slightly
less than a 2-fold increase in ocular chlamydia reinfection over 3 years. Several factors may
Fig 3. Longitudinal prevalence of trachomatous inflammation–follicular in children aged 0–9 years. Black line is the mean in all communities. Grey lines are the
prevalence in each community.
https://doi.org/10.1371/journal.pmed.1002633.g003
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explain these results. Communities in the present study were treated with mass azithromycin
distributions for an additional year, which may have resulted in more sustained reduction of
infection. Clusters of communities in the same district were initially treated identically in the
present study, which would have reduced infection in neighboring communities and could
have slowed reemergent infection. We cannot rule out the possibility of differences in the
underlying strength of transmission between the Gurage zone and the Amhara Region. As has
been seen in other longitudinal assessments, the correlation of infection prevalence over time
is low at lower levels of infection [16,27], and thus there was noise in trends in individual com-
munity prevalence. Finally, the presence of a secular trend could have reduced reinfection
independently from the mass azithromycin treatments.
Mathematical models have suggested that biannual mass distributions might be sufficient
to completely eliminate infection, even in severely affected areas where annual treatment is not
[5,9,10,28,29]. We did not find that to be the case in this setting. In approximately one-half of
the communities, we were able to identify infection from a sample of children even after 7
years of mass treatments. Several possibilities could explain the failure to eliminate trachoma.
Infection could have been introduced from people not included in the control program,
including those living in neighboring districts or those in the study district who did not partic-
ipate in the program. Alternatively, relatively poor water and sanitation conditions may have
promoted transmission [4,30,31]. Another possibility is that in this hyperendemic setting,
even biannual treatment is not enough to completely eliminate infection from those most
likely to transmit infection (e.g., preschool children) and that more intensive treatments are
necessary specifically for these hyper-transmitters in the community.
Longer-term distribution of mass azithromycin may increase selection for macrolide resis-
tance. Although previous studies have not demonstrated an increase in resistance selection in
Chlamydia trachomatis, evidence is limited [32,33]. If multiple years of mass azithromycin dis-
tribution increase the probability of resistance selection in C. trachomatis, the efficacy of mass
azithromycin distribution may wane over time. Mass distribution of azithromycin for tra-
choma control has previously been shown to lead to selection for macrolide resistance in non-
target organisms including Streptococcus pneumoniae and Escherichia coli, and resistance
declines following cessation of antibiotics [34–37]. Monitoring of macrolide resistance selec-
tion in communities receiving long-term mass azithromycin distribution may be important
for understanding if multiple rounds of treatment have adverse effects on treatment efficacy.
The results of this study must be considered in the context of several limitations. First, in all
communities, infection increased from the end of TANA I until the beginning of TANA II,
perhaps in part because of an approximately 6-month lag between the end of TANA I and the
beginning of TANA II. Second, this study focused on evaluation of continuation versus dis-
continuation of mass azithromycin, and did not evaluate combined strategies such as the effi-
cacy of azithromycin in the presence of the facial cleanliness and environmental improvement
components of the SAFE strategy. In the study communities, facial cleanliness and environ-
mental improvement initiatives were implemented by the Ethiopian government, but we did
not monitor their implementation or community adherence to these components. Note that
while facial cleanliness and environmental conditions have been associated with decreases in
clinically active trachoma, we have no evidence that facial hygiene or environmental programs
have any effect on ocular chlamydial infection [38]. Ongoing work is evaluating the efficacy of
facial cleanliness and environmental improvement for trachoma control (ClinicalTrials.gov
NCT02754583, Principal Investigator J. Keenan). Third, these results are likely not generaliz-
able to settings with hypo- or mesoendemic trachoma, where infection may be disappearing
on its own and may not return after several rounds of mass azithromycin distribution [9,39].
Other hyperendemic areas may have different transmission characteristics, and may thus
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respond differently after repeated mass azithromycin distribution. The results are, however,
generalizable to similar regions of Ethiopia, which has the highest burden of trachoma in the
world and which will provide the world’s biggest challenge for trachoma elimination.
Four years of repeated mass azithromycin distributions greatly reduced the prevalence of
ocular chlamydia in 0- to 9-year-old children, to approximately 3%. Upon cessation of treat-
ments, infection rebounded. Reducing infection to a low level will not in itself prevent infec-
tion from rebounding in this setting. Communities in which annual or biannual mass
distributions were continued for an additional 3 years experienced stabilization of infection
and clinical disease, suggesting that antibiotics alone may not be enough to completely elimi-
nate infection in severely affected areas. However, continuing mass azithromycin distribution
after 3–5 years is significantly better for maintaining low levels of ocular chlamydia than is dis-
continuing treatment.
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